RxDoctor Payments Data

Stephanie Deavila

Family · Colorado Springs, CONPI 1740908151

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,538in general payments, 2019–2025

Across 318 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Amgen$939
  • Novartis$630
  • AbbVie$498
  • Lilly USA, LLC$475
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,43999%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,538 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$75,172
JardianceEmpagliflozin21$32,747
MounjaroTirzepatide23$29,924
LinzessLinaclotide18$25,264
TrulicityDulaglutide14$22,410
FarxigaDapagliflozin Propanediol18$20,843
Repatha SureclickEvolocumab13$20,031
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$19,768
EliquisApixaban15$19,731
GemtesaVibegron12$17,138
VascepaIcosapent Ethyl15$13,633
Venlafaxine Hcl ErVenlafaxine Hcl19$3,464
Ezetimibe83$2,173
Rosuvastatin Calcium204$2,156
Omeprazole120$1,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,038$75,17275 claims
Lilly USA, LLCMounjaro, Trulicity$475$52,33437 claims
Boehringer IngelheimJardiance$329$32,74721 claims
AbbVieLinzess, Synthroid$498$26,28933 claims
AstraZenecaFarxiga$1,154$20,84318 claims
GSKTrelegy Ellipta$32$19,76815 claims
PfizerEliquis$104$19,73115 claims
Sumitomo Pharma America, Inc.Gemtesa$87$17,13812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →